ACYW135群脑膜炎球菌多糖疫苗是我国于21世纪新研制的疫苗,用于预防由相应群脑膜炎球菌引起的疾病[1-2]。我国对疫苗实行批签发监管制度,2007年签发了第1批ACYW135群脑膜炎球菌多糖疫苗,迄今为止,由2007年的1家企业至今已有5家企业获得了生产文号,共签发近500批制品约4 000万人份。仅2013年,该疫苗批签发85批次,共计7 484 833人份。 ACYW135 meningococcal polysaccharide vaccine is a newly developed vaccine in China in the 21st century, which is used to prevent the disease caused by the corresponding group of meningococci [1-2]. In China, the vaccine batch approval regulation was issued. In 2007, the first group of ACYW135 meningococcal polysaccharide vaccine was issued. Up to now, five enterprises have obtained production numbers from a single enterprise in 2007 and have issued nearly 500 Approximately 40 million batches of products. In 2013 alone, the vaccine batch was issued in 85 batches, for a total of 7,484,833 persons.